Albert David Limited has announced a significant leadership change with the resignation of its Managing Director and Chief Executive Officer. The pharmaceutical company, which manufactures allopathic and herbal formulations, I.V. infusions, and medical disposables, informed the stock exchanges about this development on December 18, 2025.

Leadership Transition Details

The Board of Directors accepted the resignation of Mr. Umesh Manohar Kunte from his multiple roles within the company during their meeting held on December 18, 2025. The resignation encompasses his positions as Managing Director, Chief Executive Officer, and Director.

Regulatory Compliance and Communication

The resignation was communicated to both BSE Limited (Scrip Code: 524075) and National Stock Exchange of India Limited (Symbol: ALBERTDAVD) under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The board meeting that addressed this matter commenced at 17:00 hours IST and concluded at 19:20 hours IST on December 18, 2025.

With Mr. Kunte's resignation, he will also cease to be a Key Managerial Person under the provisions of Section 203 and other applicable provisions of the Companies Act, 2013. This change also affects his status under Regulation 30(5) of the SEBI Listing Regulations for determining materiality of events and information for disclosure to stock exchanges.

Official Resignation Letter

In his resignation letter dated December 18, 2025, addressed to the Chairman and Board of Directors, Mr. Kunte stated his intention to resign from the board and from the post of Managing Director CEO due to personal reasons and priorities. He requested the company to complete the necessary formalities to relieve him from his duties.

Mr. Kunte expressed gratitude in his resignation communication, thanking the entire Board and Albert David Limited family for what he described as a "wonderful and fruitful association." He also extended his wishes for the company's future success in all endeavors.

Company's Response

Albert David Limited has placed on record its deep sense of appreciation for the services rendered by Mr. Kunte and acknowledged his contributions to the company during his tenure. The company secretary and compliance officer, Lalit Lohia, signed the regulatory filing communicating this development to the stock exchanges.

About Albert David Limited

Albert David Limited operates as a unit of the Kothari Group and is engaged in manufacturing allopathic and herbal formulations, I.V. infusions, and medical disposables. The company maintains its registered office at Block-D, 3rd Floor, Gillander House, 8, Netaji Subhas Road, Kolkata-700001, and operates factories in Kolkata and Ghaziabad, with sales depots in Kolkata, Lucknow, and Patna.

Albert David Limited , a pharmaceutical manufacturing company, has announced its unaudited financial results for the second quarter and half-year ended September 30, 2025. The company reported a decline in revenue but managed to narrow its losses compared to the previous quarter.

Financial Highlights

Revenue and Profitability

Albert David Limited's revenue from operations for Q2 FY26 stood at Rs. 5,857.00 lakhs, marking a decrease from Rs. 7,056.64 lakhs in the previous quarter. Despite the revenue decline, the company managed to reduce its net loss to Rs. 540.04 lakhs in Q2 FY26, compared to a loss of Rs. 779.76 lakhs in Q1 FY26.

For the half-year period ended September 30, 2025, the company reported a total revenue from operations of Rs. 13,779.18 lakhs, with a cumulative net loss of Rs. 526.71 lakhs.

Dividend Announcement

During the quarter, Albert David Limited paid a dividend of Rs. 5.00 per equity share, resulting in a total outflow of Rs. 285.36 lakhs. This dividend payout demonstrates the company's commitment to returning value to its shareholders despite challenging market conditions.

Operational Overview

Albert David Limited operates in the pharmaceutical manufacturing sector, with a single reportable segment as per Ind AS-108 "Operating Segments". The company's financial results were reviewed by the Audit Committee and approved by the Board of Directors.

Balance Sheet and Cash Flow

As of September 30, 2025, Albert David Limited reported total assets of Rs. 53,294.06 lakhs, compared to Rs. 51,141.56 lakhs as of March 31, 2025. The company's total equity stood at Rs. 39,389.66 lakhs, showing a slight increase from Rs. 39,248.34 lakhs at the end of the previous fiscal year.

The cash flow statement reveals that the company faced challenges in its operating activities, with a net cash outflow of Rs. 2,084.59 lakhs for the half-year ended September 30, 2025. However, the company saw positive cash flow from financing activities, primarily due to proceeds from current borrowings.

Management Commentary

Y. M. Kunte, Managing Director & CEO of Albert David Limited, signed off on the financial results. While specific management comments were not provided in the available data, the company's efforts to reduce losses in a challenging quarter are evident from the financial figures.

Auditor's Review

The statutory auditors have conducted a limited review of the financial results for the quarter and half-year ended September 30, 2025, as required under SEBI regulations. They have issued an unmodified review report, indicating that the financial statements are free from material misstatements.

Investors and stakeholders should note that these are unaudited results and may be subject to changes upon final audit. The pharmaceutical sector continues to face various challenges, and Albert David Limited's performance reflects the ongoing market dynamics in this industry.